Skip to main content
Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis

Fig. 4

Screening of the FDA-approved drug library for an agent that reduces the accelerated fibrosis of induced pluripotent stem cells (iPSCs)-derived fibroblasts from systemic sclerosis patients. a Primary screen searching for drugs that reduced iPSC-derived fibroblast proliferation, as measured by using the Cell Counting Kit-8 assay. b Secondary screen of the drugs selected in primary screening. The ability of the drugs to reduce the total collagen content of the iPSC-derived fibroblasts was examined by using the hydroxyproline assay. c The ability of TGF-β1 to increase the total collagen levels of iPSC-derived fibroblasts, and the ability of dactinomycin and raloxifene to reduce this augmenting ability of TGF-β1, was examined by using the hydroxyproline assay. d, e The effect of TGF-β1 treatment with dactinomycin or raloxifene on the α-SMA expression of iPSC-derived fibroblasts was examined by western blot analysis. All graphs show the mean and standard error of the mean (*p < 0.05, **p < 0.01, ***p < 0.001, as determined by Student’s t test)

Back to article page